By DrBayer.com Editorial Team
If you have been reading about erectile dysfunction treatments lately, you have probably noticed that the information landscape is uneven. Some sources present long-established medical guidance as new discoveries. Others describe preliminary findings as if the science is settled. This guide is designed to help you read that landscape more clearly — to understand what the current evidence actually says, where it is strong, where it is still developing, and what questions are worth bringing to a qualified clinician.
This article is a companion to Brazilian Hardening Secret and the Erection Muscle Trick: Fad or Functional Support?, which reviewed a widely circulated pelvic floor and supplementation protocol. The goal here is different: rather than evaluate a specific product or method, this guide maps the clinical context around ED treatment evidence so you can assess what you read against a clearer standard.
Editorial note: This article reflects evidence available as of October 2026. If the research landscape or clinical guidelines change materially, this page will be updated with a dated correction noting what changed and why.
What “Evidence Update” Actually Means in Clinical Practice
When a source describes an ED treatment as having “new evidence,” it is worth pausing to ask what kind of evidence before drawing conclusions. Not all evidence updates carry the same weight.
- A single randomized controlled trial (RCT) adds one data point. It matters more when it replicates prior findings in a similar population, and less when the study population is narrow or the comparator is weak.
- A systematic review or meta-analysis synthesizes multiple trials. This is generally more informative than any single study, but its conclusions depend on the quality of the studies it combines and whether those studies were similar enough to be pooled meaningfully.
- A clinical guideline update from a body such as the American Urological Association (AUA) or the European Association of Urology (EAU) reflects a formal panel evaluation of accumulated evidence. These updates move slowly by design — they require a consistent body of high-quality trials before changing a recommendation.
- An observational study or case series describes patterns rather than testing causes. It generates useful hypotheses but cannot establish whether a treatment works.
Understanding what kind of evidence a claim rests on is the first step toward reading it accurately. The sections below apply this frame to the main categories of ED treatment.
Established First-Line Treatment: PDE5 Inhibitors
The most established pharmacological treatments for erectile dysfunction are phosphodiesterase type 5 (PDE5) inhibitors — oral medications that improve blood flow to the penis by enhancing the body’s natural vascular response to sexual stimulation. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, identifies these as the primary medical option for most men with ED.
Both the AUA and the EAU recommend PDE5 inhibitors as first-line pharmacological treatment, a recommendation supported by Grade A evidence — the highest evidence tier these guidelines use. Several FDA-approved medications in this class are available. They differ primarily in how quickly they act and how long effects last, which affects which option suits a given person’s lifestyle and clinical situation. The choice is typically made through a shared decision between the patient and their healthcare provider.
Important points to understand before any conversation with a clinician:
- PDE5 inhibitors do not initiate an erection on their own — they require sexual stimulation to work.
- They are contraindicated with nitrate medications, which are commonly prescribed for chest pain and certain heart conditions. Combining them can cause a dangerous and potentially fatal drop in blood pressure.
- The AUA guideline specifically notes that early use of PDE5 inhibitors after prostate cancer treatment — whether radical prostatectomy or radiotherapy — may not improve spontaneous, unassisted erectile function. This nuance is frequently missing from general-audience summaries.
- When testosterone deficiency is also present, clinical guidelines indicate that testosterone therapy works best as a combination with PDE5 inhibitors, not as a standalone ED treatment.
Evidence status as of October 2026: Well-established over multiple decades of RCTs and multiple guideline cycles. No change to first-line recommendation status in the most recent guideline reviews examined for this article. The AUA guideline was most recently updated in 2024.
Lifestyle Modification: Stronger Evidence Than It Appears
Clinical guidelines consistently place lifestyle changes alongside pharmacological treatment, and the evidence supporting this is more robust than general health media tends to reflect.
The NIDDK lists physical activity, smoking cessation, limiting alcohol use, maintaining a healthy body weight, following a healthy eating plan, and avoiding recreational drugs as interventions with meaningful clinical support for ED management. The mechanism is not motivational — it is physiological. ED is frequently a vascular condition: reduced blood flow to penile tissue underlies most cases. The cardiovascular risk factors that drive heart disease (smoking, obesity, physical inactivity, poorly managed diabetes, high blood pressure) are the same factors most consistently linked to ED. Addressing them addresses the underlying physiology.
The AUA guideline includes a specific recommendation that clinicians counsel men with ED who have comorbidities known to negatively affect erectile function to make lifestyle changes, noting that such changes improve overall health and may improve erectile function. A landmark RCT examining the effect of weight loss on erectile function in obese men found that meaningful weight reduction improved or restored erectile function in a substantial proportion of participants — a finding replicated in subsequent guidelines.
For physical activity, the NIDDK references the Physical Activity Guidelines for Americans (2nd edition), which recommends at least 150 minutes of moderate-intensity activity per week. This threshold appears in clinical ED management guidance as a practical benchmark.
Evidence status as of October 2026: Consistent across multiple guidelines and RCTs. Strongest for aerobic exercise and weight management in men with relevant comorbidities. Evidence for specific dietary patterns — such as a Mediterranean-style diet — is largely observational but directionally consistent. This is an area where the evidence is more solid than most consumer content suggests.
Pelvic Floor Training: What the Research Can and Cannot Establish
The companion article on this site reviewed a protocol centered on contracting the pubococcygeus (PC) muscle as part of the pelvic floor. This section addresses what the clinical research base can actually establish about pelvic floor muscle training (PFMT) for ED.
The mechanistic rationale is well-grounded. The ischiocavernosus and bulbocavernosus muscles, which are part of the male pelvic floor, play a role in compressing penile veins during erection — a process that helps maintain rigidity. When these muscles are weak or poorly coordinated, that mechanism is less effective, sometimes described as venous leak. Targeted exercise addresses this directly.
A frequently cited RCT published in BJU International (Dunn CD, Feneley RC, Speakman MJ, Swinkels A, Dorey G; 2005; Vol. 96(4); DOI: 10.1111/j.1464-410X.2005.05690.x) enrolled 55 men with ED of at least six months’ duration and randomized them to supervised pelvic floor muscle exercises with biofeedback and lifestyle advice, or lifestyle advice alone. After three months, erectile function was significantly better in the intervention group (p < 0.001). At six months, blinded assessment showed that 40% of men had regained normal erectile function, 35.5% had improved, and 24.5% had not improved. The researchers concluded that pelvic floor exercises should be considered a first-line approach for men seeking long-term resolution of ED.
Limits of this trial worth knowing: it was small (55 men), conducted two decades ago, and excluded men whose ED was attributable to neurological injury or major urological surgery. It tested supervised physiotherapy-led training combined with lifestyle advice, not unsupervised home exercise alone.
A 2019 systematic review published in Physiotherapy (Myers C, Smith M; Vol. 105(2); DOI: 10.1016/j.physio.2019.01.002) included ten trials and concluded that PFMT appears effective for managing ED, but found that no optimal training protocol has been established and that study heterogeneity was not suitable for data pooling.
A 2024 narrative review (Exercise Science; DOI: 10.15857/ksep.2024.00066) examined seven RCTs of PFMT for ED and found that none of the seven produced a statistically significant effect when PFMT was tested in isolation. Studies that combined PFMT with biofeedback, electrical stimulation, or structured lifestyle counseling showed more consistent results.
Evidence status as of October 2026: Mechanistically sound; directionally positive across multiple trials; limited by heterogeneous protocols, small samples, and inconsistent outcome measures. Best understood as a supported adjunctive approach — particularly for men with pelvic floor weakness — rather than a universal first-line treatment. Current major clinical guidelines do not formally rank it alongside PDE5 inhibitors, but neither do they contraindicate it.
Unresolved question: What is the optimal training protocol — frequency, duration, supervised versus unsupervised, with or without biofeedback? Current evidence cannot answer this definitively.
Practical next step: If pelvic floor training is a direction you want to explore, a pelvic floor physiotherapist can assess whether your pelvic floor is weak (undertrained) or overactive (hypertonic) before prescribing a protocol — because these two presentations require different approaches.
Low-Intensity Shockwave Therapy: A Developing Evidence Category
Low-intensity shockwave therapy (LiSWT, also written LI-ESWT) has received growing attention as a potential non-pharmacological option for vasculogenic ED — the form driven by reduced blood flow. The proposed mechanism involves low-energy acoustic waves stimulating the formation of new blood vessels and improving tissue quality in the penis.
A 2025 Cochrane systematic review (Cochrane Database of Systematic Reviews, 2025, Issue 7, CD013166) provides the most rigorous synthesis published to date. It analyzed 21 RCTs involving 1,357 men aged 39 to 65. The review found that LiSWT may slightly improve short-term erectile function, with a mean difference of approximately 3.89 points on the International Index of Erectile Function — Erectile Function domain (IIEF-EF) scale compared to sham treatment (95% CI 2.89–4.89; 15 studies). Long-term function also showed a possible improvement, with a mean difference of approximately 5.25 points (95% CI 2.47–8.04; 5 studies). The Cochrane authors rated the certainty of evidence as low for all outcomes, primarily due to methodological limitations and significant heterogeneity across the included studies. They noted that clinical importance remained uncertain — meaning that whether a 3–5 point IIEF improvement translates into a meaningful difference for the patient in practice is not established.
The AUA currently classifies LiSWT as a Grade C recommendation for ED — based on expert opinion or lower-quality evidence, not on the consistent high-quality trial base that supports Grade A recommendations for PDE5 inhibitors.
A 2024 publication in the International Journal of Impotence Research (DOI: 10.1038/s41443-024-00959-7) examining optimal protocols noted that adding daily low-dose tadalafil may meaningfully improve LiSWT outcomes compared to shockwave therapy alone. A separate Bayesian network meta-analysis (DOI: 10.1038/s41443-024-00910-w; epub May 2024) analyzed energy density across 18 studies and found that one specific energy setting (0.15 mJ/mm²) produced the highest ranked improvement in IIEF-EF scores — illustrating how much the technical parameters of this treatment still matter and how much standardization is still needed.
Evidence status as of October 2026: Promising but low-certainty. Direction of effect is consistent across multiple trials; confidence is limited by heterogeneous protocols, small sample sizes, and methodological limitations. LiSWT is not FDA-approved as a standalone ED treatment in the United States. Devices and protocols in use at clinics vary considerably in quality.
Unresolved question: Which patients benefit most? Published trials have focused heavily on mild-to-moderate vasculogenic ED. Evidence in severe ED, post-surgical ED, or psychogenic ED is substantially thinner.
Other Recognized Treatment Options
The NIDDK and AUA both describe a full range of treatment options beyond oral medications and lifestyle changes. For reference:
- Vacuum erectile devices (VEDs): Mechanical devices that draw blood into the penis and use a constriction ring to maintain erection. Recognized in both AUA and EAU guidelines as a valid option, particularly for men who cannot use PDE5 inhibitors. Practical considerations include reduced spontaneity, possible temporary numbness or bruising, and some reduction in ejaculation force — which does not typically affect the sensation of orgasm, per NIDDK guidance.
- Intracavernous injection therapy: Injectable medications such as alprostadil cause a rapid erection by directly increasing blood flow to penile tissue. Highly effective in clinical trials, with a faster and more reliable onset than oral medications for some patients. Requires patient training and proper injection technique. A serious adverse effect risk is priapism — a prolonged erection lasting more than four hours — which requires immediate medical attention.
- Intraurethral suppositories: A solid form of alprostadil inserted into the urethra. A less common alternative for those who prefer to avoid injections.
- Penile prosthesis surgery: Generally considered only when all other treatments have failed. The NIDDK notes that most men with ED do not need surgery. Arterial reconstruction may be an option for younger men with focal arterial occlusion and no generalized vascular disease.
- Counseling: For men whose ED is partly or fully driven by anxiety, stress, depression, or relationship factors, the NIDDK and clinical guidelines recommend counseling as a component of treatment — sometimes alongside other approaches, sometimes as the primary one.
The appropriate option depends on the underlying cause of ED, the individual’s comorbidities, their current medications, and their preferences — factors that require evaluation by a qualified clinician.
The FDA Fraud Warning: Why It Belongs in Any Evidence Discussion
A review of ED treatment evidence is incomplete without an honest account of the supplement and “enhancement” product landscape, because it directly shapes how many men interpret treatment claims.
The FDA maintains an active notification page for sexual enhancement products that have been found to contain hidden pharmaceutical ingredients. The agency’s own statement on that page reads that “many products that claim to help with sexual enhancement or treat sexual dysfunction” are likely to be contaminated, and that the published notification list “covers only a small fraction of the contaminated products on the market.”
The most common adulterant found in these products is PDE5 inhibitors — the same class of drugs available by prescription. An undisclosed PDE5 inhibitor in a supplement can cause a dangerous or fatal interaction with nitrate medications. That risk is completely invisible from the product’s label or marketing.
The FDA also notes that these products “are sometimes falsely advertised as dietary supplements, food and/or all-natural treatments” and “often have multiple positive reviews and/or are being shared through social media.” The implication for evidence evaluation is direct: when a supplement product appears to produce dramatic results, one explanation is undisclosed drug contamination — not the herbal ingredients listed on the label. The FDA advises anyone experiencing ED to seek guidance from a healthcare provider before purchasing any product to treat this condition.
An Evidence Worksheet for Evaluating ED Treatment Claims
When you encounter a claim about an ED treatment — in an article, from a product company, or in any other context — these questions are worth working through before drawing a conclusion.
- What exactly is the claim? State it precisely. “This ingredient may support blood flow” is a different claim than “this treatment restores erectile function in men with cardiovascular disease.” The difference matters.
- What kind of source does the claim draw on? Single RCT, meta-analysis, observational study, expert opinion, or manufacturer’s summary? Each carries different evidentiary weight.
- What can this source type actually establish? A trial in healthy young men cannot establish efficacy in men with diabetes-related ED. A surrogate outcome like an IIEF score improvement is not the same as confirmed successful intercourse.
- Who was studied? Age range, ED severity (mild, moderate, severe), cause of ED (vasculogenic, psychogenic, post-surgical, mixed), comorbidities — all of these affect whether the findings are relevant to any given individual.
- What was the comparator? A treatment that performs better than placebo is not the same as a treatment that performs comparably to an established option. Both facts matter.
- What remains unresolved? Honest evidence summaries name the gaps. If a source presents no uncertainty, treat that as a signal to look further.
- What is the practical next step given what the evidence does and does not establish? For most ED treatment decisions, the next step is a conversation with a qualified clinician who can evaluate the underlying cause, assess cardiovascular risk, and review medication interactions.
Preparing for That Clinician Conversation
This guide is designed to help you arrive at that conversation better prepared — not to replace it. Questions worth having ready:
- Has the underlying cause of my ED been evaluated — vascular, hormonal, neurological, psychological, medication-related, or a combination?
- Is my cardiovascular risk profile a relevant factor in treatment choice?
- Are any of my current medications relevant to PDE5 inhibitor safety?
- Would pelvic floor evaluation be appropriate for my situation?
- Is there a newer intervention, such as LiSWT, that is appropriate for my specific presentation? If so, at what evidence level?
- What outcome measure should I use to evaluate whether a treatment is working?
The evidence described in this article gives those questions context. The answers belong in a conversation with someone qualified to evaluate your individual health picture.
The DrBayer.com Editorial Team publishes independent educational content. Editorial status does not confer medical credentials. Nothing in this article constitutes medical advice, diagnosis, or a treatment recommendation for any individual. Always consult a qualified healthcare provider before making decisions about your health or any supplement or treatment program, particularly if you have existing medical conditions or take prescription medications.